NASDAQ:KZR

Kezar Life Sciences - KZR Stock Forecast, Price & News

$6.90

+0.17 (+2.53%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $6.70
▼
$7.01
50-Day Range: $6.02
▼
$7.81
52-Week Range: $4.30
▼
$18.55

Volume: 348,342 shs
Average Volume: 679,713 shs
Market Capitalization: $471.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.33

Institutional Ownership

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 165.7% Upside
$18.33 Price Target
Short Interest: Healthy
5.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.32
Based on 7 Articles This Week
Insider Trading: Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.03) to ($1.17) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

310th out of 1,055 stocks

Pharmaceutical Preparations Industry

145th out of 519 stocks

3.5

Analyst's Opinion

Consensus Rating
Kezar Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.33, Kezar Life Sciences has a forecasted upside of 165.7% from its current price of $6.90.
Amount of Analyst Coverage
Kezar Life Sciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.66% of the outstanding shares of Kezar Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Kezar Life Sciences has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Kezar Life Sciences has recently decreased by 36.97%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kezar Life Sciences does not currently pay a dividend.
Dividend Growth
Kezar Life Sciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kezar Life Sciences is -0.85.

2.4

News and Social Media Coverage

News Sentiment
Kezar Life Sciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kezar Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,047,433.00 in company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Kezar Life Sciences is held by insiders.
Percentage Held by Institutions
84.03% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($1.03) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kezar Life Sciences is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kezar Life Sciences is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kezar Life Sciences has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

January 26, 2023 | americanbankingnews.com

Morningside Venture Investment Sells 80,000 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) Stock

January 20, 2023 | americanbankingnews.com

Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Morningside Venture Investment Sells 6,114 Shares of Stock

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 20, 2023 | americanbankingnews.com

Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Sells $33,850.00 in Stock

January 4, 2023 | finance.yahoo.com

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023 | markets.businessinsider.com

Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)

November 16, 2022 | seekingalpha.com

Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold

November 14, 2022 | finance.yahoo.com

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

November 10, 2022 | finance.yahoo.com

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 3, 2022 | finance.yahoo.com

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

October 14, 2022 | finance.yahoo.com

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting

October 4, 2022 | forbes.com

Kezar Life Sciences

October 3, 2022 | msn.com

Why Kezar Life Sciences Shares Are Volatile After Hours

October 3, 2022 | finance.yahoo.com

Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

September 29, 2022 | finance.yahoo.com

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

September 20, 2022 | nasdaq.com

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt In A Risky Way?

September 1, 2022 | finance.yahoo.com

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

August 30, 2022 | finance.yahoo.com

A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year

August 11, 2022 | finance.yahoo.com

Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

July 27, 2022 | seekingalpha.com

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

July 18, 2022 | finance.yahoo.com

Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?

July 11, 2022 | finance.yahoo.com

Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

July 8, 2022 | finance.yahoo.com

Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating

July 7, 2022 | finance.yahoo.com

Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

June 28, 2022 | finance.yahoo.com

Wells Fargo Beefs Up Kezar Life Price Target - Read Why

June 28, 2022 | finance.yahoo.com

Why Kezar Life Sciences Stock Is Crushing It Today

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings: 11/10/2022
Today: 1/27/2023
Next Earnings (Estimated): 3/16/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KZR
CUSIP: N/A
CIK: 1645666
Web: www.kezarlifesciences.com
Phone: (650) 822-5600
Fax: N/A
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.33
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $14.00
Forecasted Upside/Downside: +165.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -25.46%
Return on Assets: -23.54%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 31.15
Quick Ratio: 31.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.01 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 68,378,000
Free Float: 63,045,000
Market Cap: $471.81 million
Optionable: Not Optionable
Beta: 0.23

Key Executives

John Fowler
Chief Executive Officer & Director

Christopher J. Kirk
President, Director & Chief Scientific Officer

Michael Wolfe
Director-Finance & Business Operations

Marc L. Belsky
Chief Financial Officer & Secretary

Noreen Roth Henig
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KZR shares.
View KZR analyst ratings or view top-rated stocks.
What is Kezar Life Sciences' stock price forecast for 2023?: 2 analysts have issued 1 year price objectives for Kezar Life Sciences' stock. Their KZR share price forecasts range from $14.00 to $21.00. On average, they predict the company's stock price to reach $18.33 in the next year. This suggests a possible upside of 165.7% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.
How have KZR shares performed in 2023?: Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR stock has decreased by 2.0% and is now trading at $6.90.
View the best growth stocks for 2023 here.
Are investors shorting Kezar Life Sciences?: Kezar Life Sciences saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 3,870,000 shares, a decrease of 37.0% from the December 31st total of 6,140,000 shares. Based on an average daily trading volume, of 646,800 shares, the short-interest ratio is currently 6.0 days.
View Kezar Life Sciences' Short Interest.
When is Kezar Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our KZR earnings forecast.
How were Kezar Life Sciences' earnings last quarter?: Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings data on Thursday, November, 10th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01.

What other stocks do shareholders of Kezar Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).
When did Kezar Life Sciences IPO?: (KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.
What is Kezar Life Sciences' stock symbol?: Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."
How do I buy shares of Kezar Life Sciences?: Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kezar Life Sciences' stock price today?: One share of KZR stock can currently be purchased for approximately $6.90.
How much money does Kezar Life Sciences make?: Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $471.81 million. The company earns $-54,630,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.
How can I contact Kezar Life Sciences?: Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kezar Life Sciences - KZR Stock Forecast, Price & News

Kezar Life Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kezar Life Sciences (NASDAQ:KZR) Stock

KZR Stock News Headlines

KZR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KZR Stock - Frequently Asked Questions

Overall MarketRank^™